Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein



| Description | |
|---------------------|--|
| Source | Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus. |
| | It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide. |
| Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK |
| Molecular Weight | The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result. |
| Endotoxin | Less than 1EU per μg by the LAL method. |
| Purity | > 95% as determined by Tris-Bis PAGE |
| | > 95% as determined by HPLC |

Formulation and Storage

Formulation Supplied as 0.22 µm filtered solution in PBS (pH 7.4).


Storage Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.


Assay Data

Tris-Bis PAGE



Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer is greater than 95% as determined by SEC-HPLC.